CEL-SCI Corporation (CVM) stock declined over -4.21% intraday to trade at $4.32 a share on AMEX. The stock opened with a loss of -7.10% at $4.7 and touched an intraday high of $5.016, falling -6.49% against the last close of $4.62. The stock went to a low of $4.44 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-09-29
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
CEL-SCI Corporation (AMEX: CVM) stock price is $4.32 as of the last check on Wednesday, August 17. During the trading session, CVM stock reached the peak price of $5.016 while $4.44 was the lowest point it dropped to.
The AMEX listed CVM is part of Biotechnology industry that operates in the broader Health Care sector. CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer.
Mr. Geert R. Kersten
CEO, Principal Accounting & Financial Officer, Treasurer and Director
Mr. Geert R. Kersten Esq.
Chief Exec. & Financial Officer, Treasurer and Director
Ms. Patricia B. Prichep
Sr. VP of Operations & Corp. Sec.
Dr. Eyal Talor Ph.D.
Chief Scientific Officer
CVM stock traded closed the last session at $4.51, which is -$0.1899999999999995 or -4.212860310421275% lower than its previous close of $4.62. CVM's current trading price is 81.12% lower than its 52-week high of $12.9 where as its distance from 52-week low of 2.49% is -65.04%.
Number of CVM employees currently stands at -. CVM operates from 8229 Boone Boulevard, Suite 802, Vienna, VA 22182, United States.
Official Webiste of $CVM is: https://cel-sci.com
CVM stock volume for the day was 417,493 shares while in the previous session number of CVM shares traded was 347,873 . The average number of CVM shares traded daily for last 3 months was 636.58 Thousands.
The percentage change in CVM stock occurred in the recent session was -4.212860310421275% while the dollar amount for the price change in CVM stock was -$0.1899999999999995.
In the recent session, the day high for CVM stock was $5.016 while the low for CVM stock touched on the day was $4.44.
The market value of CVM currently stands at 187.44 Million with its latest stock price at $4.32 and 43.24 Million of its shares outstanding.